SparingVision Took EIC Accelerator Aid for Gene Therapy, Then €75M

Retinitis pigmentosa, a rare inherited disease that blinds young people and adults, can be caused by mutations in any one of dozens of genes, and a gene therapy that replaces one faulty gene helps only the few patients who carry it. SparingVision, a Paris company spun out of the Institut de la Vision, wants to treat all of them with one injection. In April 2019 the European Commission selected it in the EIC SME Instrument Phase 2 round, and the EU contributed €2,470,715.45 towards SIROCO, a €3.53 million project to take its lead product, SPVN06, into a first human trial.

When it announced the grant on 9 July 2019, the company said clinical batches were being produced "to initiate first clinical trials in Europe and in the U.S. in 2020", according to its release and the Foundation Fighting Blindness, an investor. The trial, called PRODYGY, started on 12 April 2023, according to ClinicalTrials.gov, nine months after the EU project had ended. On 9 February 2026 SparingVision said it had finished dosing, and that the first efficacy readout is expected in 2027, according to its announcement and Ophthalmology Times.

Where SparingVision Stands Now

SparingVision is active and has two products in human trials, but no product on the market and no revenue. The French business register shows it as an active company with its seat in Paris, a net loss of €30,351,068 in 2025 and no turnover, according to the state's company directory; Societe.com gives the same 2025 loss and a 2024 loss of €22.42 million. No insolvency or collective proceedings appear in either record.

PRODYGY enrolled 33 patients at six hospitals, one in Paris and five in the United States, and is active but no longer recruiting, according to ClinicalTrials.gov, which gives February 2027 as the estimated primary completion date. The company says it will start sharing data with regulators in 2026 and aims to begin a pivotal trial in 2027. Its second product, SPVN20, dosed its first patient in the NYRVANA trial in October 2025 in Belgium, according to the Foundation Fighting Blindness and Ophthalmology Times.

The Technology: Protecting Cones Whatever the Mutation

Retinitis pigmentosa first kills the rods, the cells for night and peripheral vision. The cones, which give daytime and central sight, then die as well, even though the faulty gene usually acts in the rods. In 2004 Sahel and Léveillard identified a protein made by rods, rod-derived cone viability factor (RdCVF), whose loss is the main factor leading cones to die, the CORDIS objective says. SPVN06 is an AAV vector injected once under the retina that carries the genes for RdCVF and a second protein, RdCVFL, which protects cones against oxidative stress, according to the project's final report.

The established alternative is gene replacement, such as the first FDA-approved retinal gene therapy, which corrects one mutation. CORDIS notes that this route treats "1 out of 65 mutations". SparingVision's claim is that SPVN06 can work regardless of the mutation and might also slow dry age-related macular degeneration. PRODYGY, however, enrolled only patients with mutations in the PDE6A, PDE6B or RHO genes, according to Clinical Trials Arena, so the gene-independent claim has not yet been tested in a broad population. Whether SPVN06 preserves vision at all will only be known from the 2027 data; so far the company has reported safety, not efficacy.

SPVN20 targets the late stage of the disease, when cones are still alive but no longer respond to light. It is injected into the vitreous and makes those cones produce a GIRK potassium channel so that they can react to light again, according to the Foundation Fighting Blindness. It came from Gamut Therapeutics, a spin-out of Deniz Dalkara's lab at the Institut de la Vision, which SparingVision agreed to buy mostly with its own shares in April 2021, according to BioPharma-Reporter and Goodwin, the law firm on the deal. The register records Gamut as merged into SparingVision in June 2021, according to Societe.com.

What SIROCO Promised, and What CORDIS Shows

The European Commission's list of winners of the 3 April 2019 cut-off names SparingVision as the only company in SIROCO. The company said in 2019 that only 4 of 136 French proposals were selected in that round. The grant agreement was signed on 29 November 2019, and the project ran from 1 August 2019 to 31 July 2022. It set five work packages: produce two pilot batches and a clinical batch, extend a natural history study of patients, run a Phase I trial in France and the US to assess "safety, tolerability and efficacy", meet regulatory requirements, and prepare market access, according to the CORDIS report.

The report for the last period, August 2021 to July 2022, lists the manufacturing work as done: a GMP master cell bank, pilot batches and a released GMP clinical batch that passed 12-month stability testing. The first natural history study, Phenorod1, covered 110 patients and Phenorod2 enrolled 86. On the trial itself, the report lists preparation, not treatment: a protocol, an investigator brochure, applications to the French and US regulators, an investigational new drug filing with the FDA and contracts with vendors. The French site contract was still being negotiated when the project closed. The report also records a "novel development plan upon Regulatory feedback" and an amendment to the grant.

1. Pilot and clinical batchesDeliveredGMP clinical batch produced and released, per CORDIS.
2. Natural history studiesDeliveredPhenorod1 with 110 patients completed; Phenorod2 enrolled 86 and was presented at ARVO 2022.
3. Regulatory filingsDeliveredIND and CTA submitted during the project; trial registered in February 2023.
4. Phase I trial within the projectNot achievedNo patient was dosed before the project ended in July 2022; dosing began in April 2023.
5. Efficacy in patientsPendingSafety reported as favourable; efficacy readout expected in 2027.

The EIC treated the result as enough. SparingVision announced on 20 April 2023 that it had received the final tranche of the grant, linked to "the successful completion of the development of SPVN06 up to clinical stage", according to its release. The amount of that tranche was not disclosed. Measured against the work plan, SIROCO delivered the manufacturing, natural history and regulatory work, but the human trial, the centre of the plan, started only after the EU money had been spent, and its efficacy question is still open.

What SparingVision Has Achieved Since the Award

The venture money came after the EU grant. In October 2020 SparingVision raised €44.5 million in a round led by 4BIO Capital and UPMC Enterprises, with Jeito Capital and Ysios Capital joining Bpifrance and the Foundation Fighting Blindness; Stéphane Boissel moved from chairman to chief executive, replacing co-founder Florence Allouche, according to the company's release and BioSpace. That release scheduled the first-in-human study for 2021, a year later than the 2019 promise.

In October 2021 Intellia Therapeutics granted SparingVision exclusive rights to its in vivo CRISPR/Cas9 editing for up to three eye targets in return for a 10% stake, milestones and royalties, according to BioPharm International and The Pharma Letter. In September 2022 Jeito Capital and UPMC Enterprises co-led a €75 million Series B, which the company said would fund first-in-human trials of SPVN06 and SPVN20, according to Goodwin and The Pharma Letter.

No priced round has been announced since. PitchBook lists a later-stage round of $40.3 million dated 30 June 2025; SparingVision has not announced it, and the figure could not be verified. The register does show a capital increase on 20 June 2025, with registered share capital rising from €1,174,027 to €1,463,363, and smaller increases through 2026, according to legal notices compiled by Societe.com and the capital history on North Data. Nominal capital does not show how much money was paid in.

The clinical record since 2023 is steady but slower than each stated plan. In August 2023 the company reported a favourable safety profile in the first three patients and expected the primary endpoint and preliminary efficacy results in 2025, according to Clinical Trials Arena and the company's release. In January 2025 an independent safety board cleared the move to the Phase II step, according to Biotech Spain. The efficacy readout is now set for 2027.

In April 2025 the company said the FDA had agreed in a Type C meeting that its data package could support a Phase II trial of SPVN06 in geographic atrophy, the advanced form of dry age-related macular degeneration, according to its release and Biotech Spain. No such trial appears among the company's studies on ClinicalTrials.gov, which lists PRODYGY, the SPVN20 trial and natural history studies. The company appointed Kali Stasi as chief medical officer in June 2025.

Why Europe Should Care

Gene therapies for rare eye diseases are the kind of advanced therapy medicinal product that the Commission's proposed European Biotech Act of December 2025 aims to bring to market faster, including by removing the extra 50-day assessment period for such products, according to White & Case. SparingVision is a case study in why Brussels worries: a French research spin-off with French public money from Bpifrance and the EU, whose lead trial runs at five US sites and one French site, whose largest rounds were co-led by a US hospital group's venture arm, and whose CRISPR partner holds an option on US rights. The science and the company stay in Paris; much of the clinical work and the potential commercial upside lie across the Atlantic.

The Verdict

SparingVision has not been asked for comment for this article. It is based entirely on public records, company statements and EU project data, linked throughout.